Journal Info

Title: Jurnal Medical Aradean (Arad Medical Journal)
Abbreviated title: J. Med. Ar.
Publisher: "Vasile Goldis" University Press
Owner: Western University "Vasile Goldis" Arad, Romania
ISSN: 1224-3744
e-ISSN: 2067-7790

Ranking and Indexing

Rank: CNCSIS C (code 292) since 2010

International Database: Index Copernicus Journal Master List Value (2010): 4.66

Who's Online

We have 37 guests online

Index Databases

METFORMIN VS NO METFORMIN DIABETES TREATMENT FOR PATIENTS WITH CLINICAL ANEMIA PDF Print E-mail

METFORMIN VS NO METFORMIN DIABETES TREATMENT FOR PATIENTS WITH CLINICAL ANEMIA

This is an automatically generated default intro template - please do not edit.


General information
Title: METFORMIN VS NO METFORMIN DIABETES TREATMENT FOR PATIENTS WITH CLINICAL ANEMIA
Meta keywords:
Meta description:

Images information
Images path absolute: /var/sites/www.jmedar.ro/images/stories/com_form2content/p2/f433
Images path relative: com_form2content/p2/f433
Thumbs path absolute:
Thumbs path relative:

Fields information
Article_Title: METFORMIN VS NO METFORMIN DIABETES TREATMENT FOR PATIENTS WITH CLINICAL ANEMIA
Authors: Alexandru Fica Mircea Onel1, Coralia Adina Cotoraci1, Daniel Răducan3, Nelu-Mihai Trofenciuc1, Verboczki Gabriela Elvira1, Cristina Onel1 , Amorin Remus Popa2
Affiliation: 1"Vasile Goldiş" West University of Arad, Faculty of Medicine
2University of Oradea, Faculty of Medicine
3 "Vasile Goldiş" West University of Arad, Faculty of Pharmacy
Abstract: Metformin, which belongs to the biguanide class, is one of the most generally used oral hypoglycemic agents. Metformin is the only oral anti-diabetic agent associated with improvements in cardiovascular morbidity and mortality and is the cornerstone of medical therapy with lifestyle modification in most patients with diabetes. B12 deficiency has been recognized many years ago as an important side effect in diabetic patients who take metformin for more than 5-10 years (1). This prospective study was performed in Arad County Clinical Emergency Hospital - Hematology Section over 131 patients (aged 18-75 years) diagnosed with type 2 diabetes (termed Lot DZ) admitted to the Arad Hematology Clinic from 2014 to 2015, with a duration of diabetes mellitus of about 1-15 years. The study found that treatment with metformin in patients diagnosed with type II diabetes in combination with cyanobalamin treatment resulted in favorable outcomes.
Keywords: Diabetes, Metformin, therapy, anemia
References: 1. Jin L, Lim SW, Jin J, Chung BH, Yang CW. Effects of addition of a dipeptidyl peptidase IV inhibitor to metformin on sirolimus-induced diabetes mellitus.Transl Res 2016;S1931-5244(16)00104-3.
2. Felton AM, LaSalle J, McGill M. Treatment urgency: The importance of getting people with type 2 diabetes to target promptly. Diabetes Res ClinPract 2016;117:100-3.
3. Moreno-Ulloa A, Moreno-Ulloa J. Mortality reduction among persons with type 2 diabetes: (−)-Epicatechin as add-on therapy to metformin? Med Hypotheses 2016;91:86-9.
4. Neslusan C, Teschemaker A, Johansen P, Willis M, Valencia-Mendoza A, Puig A. Cost-Effectiveness of Canagliflozin versus Sitagliptin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus in Mexico. Value Heal Reg Issues 2015;8:8-19.
5. Qiu R, Capuano G, Meininger G. Efficacy and safety of twice-daily treatment with canagliflozin, a sodium glucose co-transporter 2 inhibitor, added on to metformin monotherapy in patients with type 2 diabetes mellitus. J ClinTranslEndocrinol 2014;1(2):54-60.
6. de Jong RGPJ, Nielen JTH, Masclee AAM, Janssen-Heijnen MLG, de Vries F. Comments on ‘Use of metformin and risk of kidney cancer in patients with type 2 diabetes’, Chin-Hsiao Tseng. Eur J Cancer 2016;52:19-25. European Journal of Cancer 2016;61:157-8.
7. Kumthekar AA, Gidwani HV, Kumthekar AB. Metformin associated B12 deficiency. JAssoc Physicians India 2012;60:58-60.
8. Nestler, J. E. (2008). Metformin for the treatment of the polycystic ovary syndrome. New England Journal of Medicine, 358(1), 47-54.
9. Aroda, V. R., Edelstein, S. L., Goldberg, R. B., Knowler, W. C., Marcovina, S. M., Orchard, T. J., ... & Crandall, J. P. (2016). Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. The Journal of Clinical Endocrinology & Metabolism, 101(4), 1754-1761.
10. Holmes, D. (2016). Diabetes: Metformin linked to vitamin B12 deficiency. Nature Reviews Endocrinology.
11. Chapman, L. E., Darling, A. L., & Brown, J. E. (2015). The association between the biguanide drug metformin and vitamin B 12 deficiency in diabetic patients: a systematic review. Proceedings of the Nutrition Society, 74(OCE1), E128.
12. Matthews, D. E., Beatty, S. J., Grever, G. M., Lehman, A., & Barnes, K. D. (2016). Comparison of 2 Population Health Management Approaches to Increase Vitamin B12 Monitoring in Patients Taking Metformin. Annals of Pharmacotherapy, 50(10), 840-846.
13. McGrath RT, Glastras SJ, Hocking S, Fulcher GR. Use of metformin earlier in pregnancy predicts supplemental insulin therapy in women with gestational diabetes. Diabetes Res ClinPract 2016;116:96-9.
14. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. (UKPDS34) UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854-65.
15. Ting RZ, Szeto CC, Chan MH, et al. Risk factors of vitamin B(12) deficiency in patients receiving metformin.Arch Intern Med 2006;166:1975-9.
16. Bell DS. Nondiabetic neuropathy in a patient with diabetes. EndocrPract 1995;1:393-4.
17. Caspary WF, Zavada I, Reimold W, et al. Alteration of bile acid metabolism and vitamin-B12-absorption in diabetics on biguanides. Diabetologia 1977;13:187-93.
18. Schäfer G. Some new aspects on the interaction of hypoglycemia-producing biguanides with biological membranes. BiochemPharmacol 1976;25:2014-24.
19. L. Jin, S. W. Lim, J. Jin, B. H. Chung, and C. W. Yang, “Effects of addition of a dipeptidyl peptidase IV inhibitor to metformin on sirolimus-induced diabetes mellitus,” Transl. Res., 2016.
20. Bauman WA, Shaw S, Jayatilleke E, et al. Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin. Diabetes Care 2000;23:1227-31.
21. Deller DJ, Witts LJ. Changes in the blood after partial gastrectomy with special reference to vitamin B12. I. Serum vitamin B12, haemoglobin, serum iron, and bone marrow. Q J Med 1962;31:71-88.
22. Valensi P, de Pouvourville G, Benard N, Chanut-Vogel C, Kempf C, Eymard E, Moisan C, Dallongeville J. Treatment maintenance duration of dual therapy with metformin and sitagliptin in type 2 diabetes: The ODYSSEE observational study. Diabetes Metab 2015;41(3):231-8.
23. L. Jin, S. W. Lim, J. Jin, B. H. Chung, and C. W. Yang, “Effects of addition of a dipeptidyl peptidase IV inhibitor to metformin on sirolimus-induced diabetes mellitus,” Transl. Res., 2016.
24. Wright JJ, Tylee TS. Pharmacologic Therapy of Type 2 Diabetes. Med Clin North Am 2016;100(4):647-63.
25. Șerban Viorel, Tratat român de boli metabilice, vol1, ed. Brumar,București 2010.
26. Șerban Viorel, Tratat român de boli metabolice, vol . 2, ed Brumar, București 2010..
27. A. Moreno-Ulloa and J. Moreno-Ulloa, “Mortality reduction among persons with type 2 diabetes: (−)-Epicatechin as add-on therapy to metformin?,” Med. Hypotheses, vol. 91, pp. 86–89, 2016.
28. R. Qiu, G. Capuano, and G. Meininger, “Efficacy and safety of twice-daily treatment with canagliflozin, a sodium glucose co-transporter 2 inhibitor, added on to metformin monotherapy in patients with type 2 diabetes mellitus,” J. Clin. Transl. Endocrinol., vol. 1, no. 2, pp. 54–60, 2014.
29. A. Strózik, A. Stęposz, M. Basiak, M. Drożdż, and B. Okopień, “Multifactorial effects of vildagliptin added to ongoing metformin therapy in patients with type 2 diabetes mellitus,” Pharmacol. Reports, vol. 67, no. 1, pp. 24–31, 2015.
30. K. Y. Thong, P. Sen Gupta, A. D. Blann, and R. E. J. Ryder, “The influence of age and metformin treatment status on reported gastrointestinal side effects with liraglutide treatment in type 2 diabetes,” Diabetes Res. Clin. Pract., vol. 109, no. 1, pp. 124–129, 2015.
31. Correia, S., Carvalho, C., Santos, M. S., Seica, R., Oliveira, C. R., & Moreira, P. I. (2008). Mechanisms of action of metformin in type 2 diabetes and associated complications: an overview. Mini reviews in medicinal chemistry, 8(13), 1343-1354.
Read_full_article: pdf/vol20/iss1/4 JMA  - Onel - ARAD 2.pdf
Correspondence: Onel Alexandru Fica Mircea
E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Read full article
Article Title: METFORMIN VS NO METFORMIN DIABETES TREATMENT FOR PATIENTS WITH CLINICAL ANEMIA
Authors: Alexandru Fica Mircea Onel1, Coralia Adina Cotoraci1, Daniel Răducan3, Nelu-Mihai Trofenciuc1, Verboczki Gabriela Elvira1, Cristina Onel1 , Amorin Remus Popa2
Affiliation: 1"Vasile Goldiş" West University of Arad, Faculty of Medicine
2University of Oradea, Faculty of Medicine
3 "Vasile Goldiş" West University of Arad, Faculty of Pharmacy
Abstract: Metformin, which belongs to the biguanide class, is one of the most generally used oral hypoglycemic agents. Metformin is the only oral anti-diabetic agent associated with improvements in cardiovascular morbidity and mortality and is the cornerstone of medical therapy with lifestyle modification in most patients with diabetes. B12 deficiency has been recognized many years ago as an important side effect in diabetic patients who take metformin for more than 5-10 years (1). This prospective study was performed in Arad County Clinical Emergency Hospital - Hematology Section over 131 patients (aged 18-75 years) diagnosed with type 2 diabetes (termed Lot DZ) admitted to the Arad Hematology Clinic from 2014 to 2015, with a duration of diabetes mellitus of about 1-15 years. The study found that treatment with metformin in patients diagnosed with type II diabetes in combination with cyanobalamin treatment resulted in favorable outcomes.
Keywords: Diabetes, Metformin, therapy, anemia
References: 1. Jin L, Lim SW, Jin J, Chung BH, Yang CW. Effects of addition of a dipeptidyl peptidase IV inhibitor to metformin on sirolimus-induced diabetes mellitus.Transl Res 2016;S1931-5244(16)00104-3.
2. Felton AM, LaSalle J, McGill M. Treatment urgency: The importance of getting people with type 2 diabetes to target promptly. Diabetes Res ClinPract 2016;117:100-3.
3. Moreno-Ulloa A, Moreno-Ulloa J. Mortality reduction among persons with type 2 diabetes: (−)-Epicatechin as add-on therapy to metformin? Med Hypotheses 2016;91:86-9.
4. Neslusan C, Teschemaker A, Johansen P, Willis M, Valencia-Mendoza A, Puig A. Cost-Effectiveness of Canagliflozin versus Sitagliptin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus in Mexico. Value Heal Reg Issues 2015;8:8-19.
5. Qiu R, Capuano G, Meininger G. Efficacy and safety of twice-daily treatment with canagliflozin, a sodium glucose co-transporter 2 inhibitor, added on to metformin monotherapy in patients with type 2 diabetes mellitus. J ClinTranslEndocrinol 2014;1(2):54-60.
6. de Jong RGPJ, Nielen JTH, Masclee AAM, Janssen-Heijnen MLG, de Vries F. Comments on ‘Use of metformin and risk of kidney cancer in patients with type 2 diabetes’, Chin-Hsiao Tseng. Eur J Cancer 2016;52:19-25. European Journal of Cancer 2016;61:157-8.
7. Kumthekar AA, Gidwani HV, Kumthekar AB. Metformin associated B12 deficiency. JAssoc Physicians India 2012;60:58-60.
8. Nestler, J. E. (2008). Metformin for the treatment of the polycystic ovary syndrome. New England Journal of Medicine, 358(1), 47-54.
9. Aroda, V. R., Edelstein, S. L., Goldberg, R. B., Knowler, W. C., Marcovina, S. M., Orchard, T. J., ... & Crandall, J. P. (2016). Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. The Journal of Clinical Endocrinology & Metabolism, 101(4), 1754-1761.
10. Holmes, D. (2016). Diabetes: Metformin linked to vitamin B12 deficiency. Nature Reviews Endocrinology.
11. Chapman, L. E., Darling, A. L., & Brown, J. E. (2015). The association between the biguanide drug metformin and vitamin B 12 deficiency in diabetic patients: a systematic review. Proceedings of the Nutrition Society, 74(OCE1), E128.
12. Matthews, D. E., Beatty, S. J., Grever, G. M., Lehman, A., & Barnes, K. D. (2016). Comparison of 2 Population Health Management Approaches to Increase Vitamin B12 Monitoring in Patients Taking Metformin. Annals of Pharmacotherapy, 50(10), 840-846.
13. McGrath RT, Glastras SJ, Hocking S, Fulcher GR. Use of metformin earlier in pregnancy predicts supplemental insulin therapy in women with gestational diabetes. Diabetes Res ClinPract 2016;116:96-9.
14. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. (UKPDS34) UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854-65.
15. Ting RZ, Szeto CC, Chan MH, et al. Risk factors of vitamin B(12) deficiency in patients receiving metformin.Arch Intern Med 2006;166:1975-9.
16. Bell DS. Nondiabetic neuropathy in a patient with diabetes. EndocrPract 1995;1:393-4.
17. Caspary WF, Zavada I, Reimold W, et al. Alteration of bile acid metabolism and vitamin-B12-absorption in diabetics on biguanides. Diabetologia 1977;13:187-93.
18. Schäfer G. Some new aspects on the interaction of hypoglycemia-producing biguanides with biological membranes. BiochemPharmacol 1976;25:2014-24.
19. L. Jin, S. W. Lim, J. Jin, B. H. Chung, and C. W. Yang, “Effects of addition of a dipeptidyl peptidase IV inhibitor to metformin on sirolimus-induced diabetes mellitus,” Transl. Res., 2016.
20. Bauman WA, Shaw S, Jayatilleke E, et al. Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin. Diabetes Care 2000;23:1227-31.
21. Deller DJ, Witts LJ. Changes in the blood after partial gastrectomy with special reference to vitamin B12. I. Serum vitamin B12, haemoglobin, serum iron, and bone marrow. Q J Med 1962;31:71-88.
22. Valensi P, de Pouvourville G, Benard N, Chanut-Vogel C, Kempf C, Eymard E, Moisan C, Dallongeville J. Treatment maintenance duration of dual therapy with metformin and sitagliptin in type 2 diabetes: The ODYSSEE observational study. Diabetes Metab 2015;41(3):231-8.
23. L. Jin, S. W. Lim, J. Jin, B. H. Chung, and C. W. Yang, “Effects of addition of a dipeptidyl peptidase IV inhibitor to metformin on sirolimus-induced diabetes mellitus,” Transl. Res., 2016.
24. Wright JJ, Tylee TS. Pharmacologic Therapy of Type 2 Diabetes. Med Clin North Am 2016;100(4):647-63.
25. Șerban Viorel, Tratat român de boli metabilice, vol1, ed. Brumar,București 2010.
26. Șerban Viorel, Tratat român de boli metabolice, vol . 2, ed Brumar, București 2010..
27. A. Moreno-Ulloa and J. Moreno-Ulloa, “Mortality reduction among persons with type 2 diabetes: (−)-Epicatechin as add-on therapy to metformin?,” Med. Hypotheses, vol. 91, pp. 86–89, 2016.
28. R. Qiu, G. Capuano, and G. Meininger, “Efficacy and safety of twice-daily treatment with canagliflozin, a sodium glucose co-transporter 2 inhibitor, added on to metformin monotherapy in patients with type 2 diabetes mellitus,” J. Clin. Transl. Endocrinol., vol. 1, no. 2, pp. 54–60, 2014.
29. A. Strózik, A. Stęposz, M. Basiak, M. Drożdż, and B. Okopień, “Multifactorial effects of vildagliptin added to ongoing metformin therapy in patients with type 2 diabetes mellitus,” Pharmacol. Reports, vol. 67, no. 1, pp. 24–31, 2015.
30. K. Y. Thong, P. Sen Gupta, A. D. Blann, and R. E. J. Ryder, “The influence of age and metformin treatment status on reported gastrointestinal side effects with liraglutide treatment in type 2 diabetes,” Diabetes Res. Clin. Pract., vol. 109, no. 1, pp. 124–129, 2015.
31. Correia, S., Carvalho, C., Santos, M. S., Seica, R., Oliveira, C. R., & Moreira, P. I. (2008). Mechanisms of action of metformin in type 2 diabetes and associated complications: an overview. Mini reviews in medicinal chemistry, 8(13), 1343-1354.
*Correspondence: Onel Alexandru Fica Mircea
E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it